Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 1, Pages e000147
Publisher
BMJ
Online
2020-03-26
DOI
10.1136/jitc-2019-000147
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Harmonization and Standardization of Panel-Based Tumor Mutational Burden (TMB) Measurement: Real-World Results and Recommendations of the QuIP Study
- (2020) Albrecht Stenzinger et al. Journal of Thoracic Oncology
- Tumor mutational burden (TMB) standardization initiatives: Recommendations for consistent TMB assessment in clinical samples to guide immunotherapy treatment decisions
- (2019) Albrecht Stenzinger et al. GENES CHROMOSOMES & CANCER
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
- (2018) Ari Vanderwalde et al. Cancer Medicine
- Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
- (2018) Kyle Ellrott et al. Cell Systems
- Size Matters: Dissecting Key Parameters for Panel-Based Tumor Mutational Burden (TMB) Analysis
- (2018) Ivo Buchhalter et al. INTERNATIONAL JOURNAL OF CANCER
- A machine learning approach for somatic mutation discovery
- (2018) Derrick E. Wood et al. Science Translational Medicine
- 131PDevelopment and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels
- (2018) K Quinn et al. ANNALS OF ONCOLOGY
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- 56PDAnalytic validation of tumor mutational burden as a companion diagnostic for combination immunotherapy in non-small cell lung cancer
- (2018) D A Fabrizio et al. ANNALS OF ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation
- (2017) Yuya Kobayashi et al. Genome Medicine
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
- (2016) M. Kowanetz et al. ANNALS OF ONCOLOGY
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Emerging targeted therapies for melanoma
- (2016) Douglas B. Johnson et al. EXPERT OPINION ON EMERGING DRUGS
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neo approaches to cancer vaccines
- (2015) L. Delamarre et al. SCIENCE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?
- (2013) Julie R. Brahmer SEMINARS IN ONCOLOGY
- BEDTools: a flexible suite of utilities for comparing genomic features
- (2010) Aaron R. Quinlan et al. BIOINFORMATICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now